Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19
- Interventions
- Drug: SHEN26 capsuleDrug: SHEN26 placebo
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1200
- Registration Number
- NCT05908071
- Locations
- 🇨🇳
The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China
Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Drug: SHEN26 dose 2Drug: SHEN26 dose 1Drug: SHEN26 placebo
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT05676073
- Locations
- 🇨🇳
Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China
🇨🇳The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China
🇨🇳Shenzhen Longhua District People's Hospital, Shenzhen, Guangdong, China
A Phase I Study of SHEN26 Capsule in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: SHEN26 capsuleDrug: SHEN26 placebo
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT05504746
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath